Phoenix Optical net profit fell by 5005.79%

3500/40 The performance of the data indicators published in the financial report of Phoenix Optics is not satisfactory, in addition to the net profit attributable to the shareholders of listed companies, gross profit margin of 12.28%, less than 3.28%, net profit margin of -5.15%, less than 5241.55%, sales expenses, administrative expenses, financial expenses totaled 175 million yuan, three fees accounted for 9.59% of revenue, Net assets per share increased by 27.02%, 1.55 yuan, down 16.18%, operating cash flow per share 0.55 yuan, up 90.03%, earnings per share -0.3 yuan, down 3100.0%.

In the main business, Phoenix Optics focuses on the two major areas of photoelectric image sensing and intelligent control, and continues to promote the integrated development of photoelectric products business, affected by the security industry, home appliance industry and vehicle industry recession and market competition, the company’s main security lens, intelligent controller products and vehicle lens operating income have declined in different amplitude. The main product orders are insufficient, the unit fixed cost is high, and the gross profit margin is declining; At the same time, the company continued to increase research and development investment and market development, research and development expenses and sales expenses increased significantly year-on-year; Resulting in operating losses.

In terms of debt status, the company is under pressure to pay debts. During the reporting period, the scale of contract liabilities increased by 34.16% from the previous quarter, and unfulfilled orders increased, which may be caused by the slow delivery of the company or the strengthening of downstream demand.

Yirui Biological, Kehua biological net profit down more than 100%

In the first half of 2023, affected by changes in domestic and foreign public health prevention and control policies, the revenue and gross profit of Yirui Biological in vitro diagnosis business declined significantly. In addition, related assets impairment provisions, coupled with investment business and other impacts, multiple factors superimposed, the company’s performance suffered losses. For the follow-up development, Yirui Biological said that it will continue to maintain the steady development of food safety rapid testing business, and vigorously expand the animal diagnosis business to achieve the improvement of the company’s operating efficiency. The operating income of Kehua Biological in the 2023 interim report increased significantly, but the net profit and cash flow fell sharply, indicating that the company’s profitability and cash flow management are facing certain pressure.

3500/40 2023 is a year full of challenges. According to the data in Table 1, the 41 listed scientific instrument companies in China have experienced the total net profit of 21.108 billion yuan attributable to shareholders of listed companies in 2022, and the index in 2023 has fallen to 16.919 billion yuan, a decline of nearly 20%. Due to the annual state budget contraction, shrinking market demand, cooling financing environment and other multiple adverse factors interwoven, the industry frequently reported operating difficulties, lower expectations, salary cuts and staff streamlining news. Faced with this situation, enterprises urgently need to seek innovative breakthroughs and strategic adjustments to cope with the complex and changing market environment.

At present, cutting-edge technologies such as artificial intelligence and quantum information have injected unprecedented innovative vitality into the field of high-end instruments and opened up a new space for development. They should seize this opportunity, focus on the cultivation and application of new quality productivity, drive industrial upgrading and transformation, accelerate towards a new stage of high-quality development, ensure that they take the lead in the fierce international competition, and lead technological change and industrial innovation.